Citations

Showing 10 of 108015 citations.

Brain Death: Legal Obligations and the Courts
Pope, Thaddeus Mason , Burkle, Christopher M.

Mayo Clinic

Seminars in Neurology | April 3, 2015 | Volume: 35 | Issue: 02 | Pages: 174-179

10.1055/s-0035-1547537 | PMID 25839727 Get It

Simulation Training in Brain Death Determination
Hocker, Sara E. , Hocker, Sara, Wijdicks, Eelco F. M.

Mayo Clinic

Seminars in Neurology | April 3, 2015 | Volume: 35 | Issue: 02 | Pages: 180-188

10.1055/s-0035-1547535 | PMID 25839728 Get It

The Clinical Determination of Brain Death: Rational and Reliable
Wijdicks, Eelco F. M.

Mayo Clinic

Seminars in Neurology | April 3, 2015 | Volume: 35 | Issue: 02 | Pages: 103-104

10.1055/s-0035-1547531 | PMID 25839718 Get It

Neurological Aspects of Human Glycosylation Disorders
Freeze, Hudson H. , Eklund, Erik A. , Patterson, Marc C. , Ng, Bobby G. , Freeze, Hudson H , Patterson, Marc

Mayo Clinic

Annual Review of Neuroscience | April 3, 2015 | Volume: 38 | Issue: 1 | Pages: 105-125

10.1146/annurev-neuro-071714-034019 | PMID 25840006 Get It

This review presents principles of glycosylation, describes the relevant glycosylation pathways and their related disorders, and highlights some of the neurological aspects and issues that continue to challenge researchers. More than 100 rare human genetic disorders that result from deficiencies in the different glycosylation pathways are known today. Most of these disorders impact the central and/or peripheral nervous systems. Patients typically have developmental delays/intellectual disabilities, hypotonia, seizures, neuropathy, and metabolic abnormalities in multiple organ systems. Among these disorders there is great clinical diversity because all cell types differentially glycosylate proteins and lipids. The patients have hundreds of misglycosylated products, which afflict a myriad of processes, including cell signaling, cell-cell interaction, and cell migration. This vast complexity in glycan composition and function, along with the limited availability of analytic tools, has impeded the identification of key glycosylated molecules that cause pathologies. To date, few critical target proteins have been pinpointed.
Brain Death Guidelines Explained
Wijdicks, Eelco F. M.

Mayo Clinic

Seminars in Neurology | April 3, 2015 | Volume: 35 | Issue: 02 | Pages: 105-115

10.1055/s-0035-1547532 | PMID 25839719 Get It

Analysis of the Constraint Joint Loading in the Thumb During Pipetting
Wu, John Z. , Sinsel, Erik W. , Zhao, Kristin D. , An, Kai‐Nan , Buczek, Frank L., Trentadue, Taylor P

Mayo Clinic

Journal of Biomechanical Engineering | April 3, 2015 | Volume: 137 | Issue: 8 | Pages: No page available

10.1115/1.4030311 | PMID 25839321 Get It

Dynamic loading on articular joints is essential for the evaluation of the risk of the articulation degeneration associated with occupational activities. In the current study, we analyzed the dynamic constraint loading for the thumb during pipetting. The constraint loading is considered as the loading that has to be carried by the connective tissues of the joints (i.e., the cartilage layer and the ligaments) to maintain the kinematic constraints of the system. The joint loadings are solved using a classic free-body approach, using the external loading and muscle forces, which were obtained in an inverse dynamic approach combined with an optimization procedure in anybody. The constraint forces in the thumb joint obtained in the current study are compared with those obtained in the pinch and grasp tests in a previous study (Cooney and Chao, 1977, “Biomechanical Analysis of Static Forces in the Thumb During Hand Function,” J. Bone Joint Surg. Am., 59(1), pp. 27–36). The maximal compression force during pipetting is approximately 83% and 60% greater than those obtained in the tip pinch and key pinch, respectively, while substantially smaller than that obtained during grasping. The maximal lateral shear force is approximately six times, 32 times, and 90% greater than those obtained in the tip pinch, key pinch, and grasp, respectively. The maximal dorsal shear force during pipetting is approximately 3.2 and 1.4 times greater than those obtained in the tip pinch and key pinch, respectively, while substantially smaller than that obtained during grasping. Our analysis indicated that the thumb joints are subjected to repetitive, intensive loading during pipetting, compared to other daily activities.
Biodegradable and crosslinkable PPF–PLGA–PEG self-assembled nanoparticles dual-decorated with folic acid ligands and Rhodamine B fluorescent probes for targeted cancer imaging
Liu, Xifeng , Yaszemski, Michael J. , Lu, Lichun , Miller, A. Lee , Miller, Alan Lee

Mayo Clinic

RSC Advances | April 3, 2015 | Volume: 5 | Issue: 42 | Pages: 33275-33282

10.1039/c5ra04096e | PMID 35330847 Get It

Novel crosslinkable self-assembled PPF–PLGA–PEG nanoparticles with fluorescent RhB probes and FA ligands for targeted cancer imaging and potential drug delivery.
Intravitreal Aflibercept after Bilateral Bevacizumab‐Induced Iritis
Skorin, Leonid , Genereux, Lucas

Mayo Clinic

Optometry and Vision Science | April 3, 2015 | Volume: 92 | Issue: 5 | Pages: No page available

10.1097/opx.0000000000000568 | PMID 25871873 Get It

ABSTRACT Purpose To present a case of neovascular age‐related macular degeneration treated with aflibercept intravitreal injections after bilateral bevacizumab injections, administered on separate dates, resulted in bilateral iritis. Case Report A 73‐year‐old woman with a previous history of two episodes of nongranulomatous iritis in her right eye that was believed to be associated with her systemic diagnosis of rheumatoid arthritis was treated with intravitreal bevacizumab injections for bilaterally occurring neovascular age‐related macular degeneration. Initial bevacizumab injections in each eye administered sequentially over a week's time resulted in immediate‐onset nongranulomatous iritis in each eye. Subsequent intravitreal injections of aflibercept were administered, and therapeutic benefit was achieved without occurrence of iritis. Conclusions In cases where intravitreal bevacizumab results in anterior uveitis, aflibercept may be a safe alternative therapeutic choice for the treatment of neovascular age‐related macular degeneration.
The Standardization Approach in End-of-Life Withdrawal of Life-Sustaining Treatment
Rady, Mohamed Y. , Verheijde, Joseph L.

Mayo Clinic

Journal of Intensive Care Medicine | April 3, 2015 | Volume: 31 | Issue: 4 | Pages: 290-292

10.1177/0885066615578407 | PMID 25835021 Get It